Galapagos raises €18 million
This article was originally published in Scrip
Executive Summary
Galapagos has raised €18.2 million through a share placement with international institutional investors. It will use the cash for clinical trials, including next year's Phase II study of its novel drug candidate GLPG0259 for rheumatoid arthritis.